PRO DEX INC
Close on Oct 19, 2026
- Market cap
- $193.98M
- P/E (TTM)
- 14.0
- Dividend yield
- –
About Pro Dex
Surgical & Medical Instruments & Apparatus, SIC 3841
Pro-Dex designs, develops, and manufactures specialized surgical devices, operating as a single business segment. Its core products include autoclavable, electric, and battery-powered multi-function surgical drivers and shavers used in thoracic, orthopedic, and craniomaxillofacial medical procedures. The company also produces rotary air motors, provides non-recurring engineering, consulting, and repair services, and fabricates precision machined components and assemblies for aerospace and defense applications. It primarily serves medical device distributors, original equipment manufacturers, commercial aerospace and defense customers, and the United States government.
The company is headquartered in Irvine, California, and maintains manufacturing and machining operations across facilities located in Irvine, Tustin, and Costa Mesa, California. Pro-Dex employs 206 individuals, five of whom work part-time, with all but four employees working at its facilities within the state of California.
Summary of the business section of Pro Dex's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PRO DEX INC
- Founded
- 1994
- Headquarters
- Irvine, CA
- Address
- 2361 Mcgaw Avenue 92614
- Phone
- (949) 769-3231
- Website
- pro-dex.com
- Employees
- 181, Jun 30, 2026
- Industry
- Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- June 30
- Auditor
- Baker Tilly US, LLP, Irvine, California
Stock & identifiers
- Ticker
- PDEX
- Exchange
- Nasdaq
- Shares outstanding
- 3M, Sep 2, 2026
- Public float
- $67.80M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-3 reverse, Jun 18, 2010
- SEC CIK
- 788920
- CUSIP
- 74265M205
- ISIN
- US74265M2052
- LEI
- 529900EB2AJA079NT411
- EIN
- 84-1261240
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kirk Richard Lee Van Jr | Chief Executive Officer, Director | 79,703 |
| Alisha Charlton | Chief Financial Officer | 22,670 |
| Angelita Rebamontan Domingo | Director | 18,798 |
| Katrina Marie Kramer Philp | Director | 19,796 |
| David Hovda | Director | 4,300 |
| Raymond E. Cabillot | Director | 272,846 |
| William James Farrell III | Director | 7,100 |
| Nicholas John Swenson | Director | 1,024,343 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Rick | $652.95K | $1.95M | $357.83K | $271 | – |
| FY2024 Rick | $441.30K | $397.48K | $320.50K | $122 | – |
| FY2023 Rick | $418.61K | $632.14K | $297.61K | $119 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“At June 30, 2025 we had 181 employees,”
Corporate history
Events identified from SEC filings